Tech Company Financing Transactions
Macrolide Pharmaceuticals Funding Round
Novartis Venture Fund, Roche Venture Fund and SR One Capital Management participated in a $22 million Series A venture round for Macrolide Pharmaceuticals. This VC investment round was announced on 3/5/2015.
Transaction Overview
Company Name
Announced On
3/5/2015
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds of the financing will enable Macrolide Pharmaceuticals to expand its proprietary drug discovery platform and accelerate the development of a pipeline of novel antibiotics.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
480 Arsenal St. 130
Watertown, MA 02472
USA
Watertown, MA 02472
USA
Phone
Website
Email Address
Overview
Macrolide Pharmaceuticals, LLC. is a new anti-infective company founded to advance groundbreaking technology developed by Professor Andrew Myers of Harvard University.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mahesh Karande
Chief Financial Officer
Andrew Littlehale
Vice President
Richard Alm
Vice President
Roger Clark
VP - Engineering
Yoshitaka Ichikawa
Browse more venture capital transactions:
Prev: 3/5/2015: Pulmokine venture capital transaction
Next: 3/5/2015: ViewRay venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs